By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
IndebtaIndebta
  • Home
  • News
  • Banking
  • Credit Cards
  • Loans
  • Mortgage
  • Investing
  • Markets
    • Stocks
    • Commodities
    • Crypto
    • Forex
  • Videos
  • More
    • Finance
    • Dept Management
    • Small Business
9
Notification Show More
Videos
How higher lumber prices will impact homebuilders
20 minutes ago
News
Box, Inc. 2026 Q1 – Results – Earnings Call Presentation (NYSE:BOX)
47 minutes ago
News
When bitcoin is the business model, investors should beware
1 hour ago
News
Donald Trump warns Vladimir Putin he is ‘playing with fire’ in Ukraine
2 hours ago
News
Nvidia’s suppliers resolve AI ‘rack’ issues in boost to sales
3 hours ago
News
McKinsey sheds 10% of staff in two-year profitability drive
4 hours ago
News
TPG and Blackstone offered $16bn to take health group Hologic private
5 hours ago
News
Citadel Securities profits jump 70% on surge in trading revenues
6 hours ago
News
US stocks jump as Donald Trump touts ‘positive’ progress on EU trade talks
7 hours ago
Aa
IndebtaIndebta
Aa
  • Banking
  • Credit Cards
  • Loans
  • Dept Management
  • Mortgage
  • Markets
  • Investing
  • Small Business
  • Videos
  • Home
  • News
  • Banking
  • Credit Cards
  • Loans
  • Mortgage
  • Investing
  • Markets
    • Stocks
    • Commodities
    • Crypto
    • Forex
  • Videos
  • More
    • Finance
    • Dept Management
    • Small Business
Follow US
Indebta > Investing > Bristol_Myers says FDA has accepted its non-small lung cancer treatment repotrectinib for priority review
Investing

Bristol_Myers says FDA has accepted its non-small lung cancer treatment repotrectinib for priority review

News Room
Last updated: 2023/05/30 at 2:00 PM
By News Room
Share
1 Min Read
SHARE

Bristol Myers Squibb Co.
BMY,
-0.15%
said Tuesday the U.S. Food and Drug Administration has accepted for priority review its application for repotrectinib as a treatment for patients with certain kinds of non-small cell lung cancer. Repotrectinib was the lead experimental drug of Turning Point Therapeutics, which Bristol Myers acquired for $3.8 billion in June of 2022. The treatment targets patients with ROS1-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) and has shown positive results in that patient group in an ongoing trial called Trident-1. If approved, the drug would provide a potential best-in-class treatment for those patients, said Bristol Myers. The FDA has set a target action date of Nov. 27. The priority review process shortens the length of time the regulator takes to approve a therapy and is used for serious illnesses with no approved treatments. Lung cancer is the leading cause of cancer deaths globally and non-small lung cancer is one of the most common types. Bristol Myers’ stock was up 0.7% premarket but has fallen 11.3% in the year to date, while the S&P 500
SPX,
-0.26%
has gained 9.5%.

Read the full article here

News Room May 30, 2023 May 30, 2023
Share this Article
Facebook Twitter Copy Link Print
Leave a comment Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Finance Weekly Newsletter

Join now for the latest news, tips, and analysis about personal finance, credit cards, dept management, and many more from our experts.
Join Now
How higher lumber prices will impact homebuilders

Watch full video on YouTube

Box, Inc. 2026 Q1 – Results – Earnings Call Presentation (NYSE:BOX)

This article was written byFollowSeeking Alpha's transcripts team is responsible for the…

When bitcoin is the business model, investors should beware

Unlock the Editor’s Digest for freeRoula Khalaf, Editor of the FT, selects…

Donald Trump warns Vladimir Putin he is ‘playing with fire’ in Ukraine

Unlock the White House Watch newsletter for freeYour guide to what Trump’s…

Nvidia’s suppliers resolve AI ‘rack’ issues in boost to sales

Unlock the Editor’s Digest for freeRoula Khalaf, Editor of the FT, selects…

- Advertisement -
Ad imageAd image

You Might Also Like

Investing

Nursing Home Stocks Could Suffer from this Medicaid Spending Remedy

By News Room
Investing

Bitcoin Drops Below $90,000 Again. What Could Move It Next.

By News Room
Investing

These Stocks Are Moving the Most Today: Marvell, Nvidia, Broadcom, GM, Tesla, MongoDB, Burlington, and More

By News Room
Investing

Nvidia Stock Falls as Marvell Earnings Compound AI Gloom. The Rising Risks for Chips.

By News Room
Investing

This analyst says Tesla deliveries will be 16% below expectations. Musk is part of the problem.

By News Room
Investing

BP CEO was awarded no bonus pay from oil giant’s financial performance

By News Room
Investing

Shares of Starlink’s European competitor have tripled. CEO says it can do the job in Ukraine.

By News Room
Investing

GE Vernova Stock Rises as Analyst Flips to Upgrade After Rating Cut

By News Room
Facebook Twitter Pinterest Youtube Instagram
Company
  • Privacy Policy
  • Terms & Conditions
  • Press Release
  • Contact
  • Advertisement
More Info
  • Newsletter
  • Market Data
  • Credit Cards
  • Videos

Sign Up For Free

Subscribe to our newsletter and don't miss out on our programs, webinars and trainings.

I have read and agree to the terms & conditions
Join Community

2023 © Indepta.com. All Rights Reserved.

Welcome Back!

Sign in to your account

Lost your password?